Gregory Kelly J, Schneider Sallie S
Pioneer Valley Life Sciences Institute, Baystate Medical Center, Springfield, Massachusetts, 01199, USA.
Biology Department, University of Massachusetts, Amherst, Massachusetts, 01003, USA.
Cell Biol Int. 2015 Jul;39(7):873-9. doi: 10.1002/cbin.10468. Epub 2015 May 5.
Estrogen has been implicated in breast cancer risk for a variety of reasons including its role in stimulating mammary cell division. Secreted frizzled-related proteins (SFRPs) are a family of Wnt signaling antagonists. Loss of Sfrp1 in mice results in focal ductal epithelial hyperplasias and in humans, loss of SFRP1 is associated with early changes in premalignant breast lesions as well as poor overall survival in patients with early stage breast cancer. Considering that SFRP1 expression is further reduced in ER positive breast cancers when compared with ER negative breast cancers, we chose to determine whether loss of Sfrp1 alters ER signaling. Immunohistochemical analysis revealed that loss of Sfrp1 significantly increased the number of PR and BrdU positve cells in the mammary gland. We further demonstrate that down stream actions of ER-mediated signaling, including cellular proliferation and PR transcription, are elevated in estradiol treated explant cultures derived from Sfrp1(-/-) mice. Additionally, we show that Control explant cultures treated with estradiol exhibit an increase in the mRNA levels of Sfrp1. Finally, we establish that in human mammary epithelial cells with either SFRP1 knocked down (TERT-siSFRP1) and rescued SFRP1 expression (MCF7-SFRP1), estrogen signaling is augmented. Modulation of ER activity appears to be through a mechanism dependent upon Wnt/β-catenin activity. Taken together, our data suggest an important control mechanism by which estrogen signaling is tempered in normal cells and indicates why loss of SFRP1 in early lesions might be a causal change leading to enhanced estrogen-mediated proliferation.
雌激素因多种原因与乳腺癌风险相关,包括其在刺激乳腺细胞分裂中的作用。分泌型卷曲相关蛋白(SFRPs)是Wnt信号拮抗剂家族。小鼠中Sfrp1的缺失会导致局灶性导管上皮增生,在人类中,SFRP1的缺失与癌前乳腺病变的早期变化以及早期乳腺癌患者的总体生存率低有关。鉴于与雌激素受体(ER)阴性乳腺癌相比,ER阳性乳腺癌中SFRP1的表达进一步降低,我们选择确定Sfrp1的缺失是否会改变ER信号。免疫组织化学分析显示,Sfrp1的缺失显著增加了乳腺中孕激素受体(PR)和溴脱氧尿苷(BrdU)阳性细胞的数量。我们进一步证明,在源自Sfrp1基因敲除(-/-)小鼠的雌二醇处理的外植体培养物中,ER介导的信号下游作用,包括细胞增殖和PR转录,均升高。此外,我们表明用雌二醇处理的对照外植体培养物中Sfrp1的mRNA水平增加。最后,我们确定在SFRP1被敲低(TERT-siSFRP1)并恢复SFRP1表达(MCF7-SFRP1)的人乳腺上皮细胞中,雌激素信号增强。ER活性的调节似乎是通过一种依赖于Wnt/β-连环蛋白活性的机制。综上所述,我们的数据表明了一种重要的控制机制,通过该机制正常细胞中的雌激素信号受到调节,并揭示了为什么早期病变中SFRP1的缺失可能是导致雌激素介导的增殖增强的因果性变化。